Stenting of Complex Lesions
“Patients with complex lesions are no longer the exception, they´re actually the majority . . . [Now] XIENCE is a solution for complex intervention.”
Chuck Simonton, MD, Abbott Vascular Chief Medical Officer
Increasingly Complex Patients Now Treated with PCI
Complex lesions and increasingly complex percutaneous coronary intervention (PCI) cases compose an ever-growing segment of the patient population.
Many complex patients are now able to benefit from minimally invasive procedures like percutaneous coronary intervention (PCI), whereas in previous years stenting of complex lesions may not have been an option. Using XIENCE in many complex patients is associated with low rates of stent thrombosis. Consequently, stenting for complex lesions may in fact expand in the future.
XIENCE for Complex Patients
XIENCE, the world’s leading drug-eluting stent (DES), is considered by industry experts to be the gold standard. It is increasingly used—and evaluated via clinical trials—in complex patients:
Given the best in class deliverability† and the expanded treatment options‡ of XIENCE Sierra, XIENCE becomes the excellent choice for these complex patients.
“The benefit of [XIENCE] occurred immediately after implantation and . . . also at long-term follow-up beyond 2 years.”
— Manel Sabaté, MD, on the EXAMINATION trial's lower event rates for XIENCE versus bare metal stents in STEMI patients6
XIENCE Complex Patient Data: Consistently Low Stent Thrombosis
Results from a number of multicenter, randomized trials reveal the efficacy and safety of XIENCE, particularly regarding low stent thrombosis (ST) rates, from 30 days to 5 years.
In fact XIENCE Sierra offers best-in-class deliverability† and is designed to treat even the most challenging lesions.
Discover more about Xience
AP2944594-WBO Rev. B